Bringing New Innovative Treatments

For dermatological and anorectal diseases.

Edesa Biotech

Founded 2015

Late-stage prescription drugs developed by Edesa Biotech aim to help patients who experience limited treatment options. Edesa Biotech’s focus on dermatology is led by an experienced team that have licensed global rights to clinical stage assets for dermatology and anorectal indications.

Download the latest Edesa Biotech Presentation(PDF | 1.2MB)

Edesa Team

Par Nijhawan, MD, FRCPC, AGAF

CEO
Dr. Nijhawan is a board-certified Gastroenterologist and Hepatologist. Prior to founding Edesa, Dr. Nijhawan was the CEO of Medical Futures Inc. which he sold to Tribute Pharmaceuticals in 2015. Dr Nijhawan completed his medical school training at the University of Ottawa and did his residency in Internal Medicine Internship at Yale-Norwalk, CT; and Internal Medicine residency and Gastroenterology and Hepatology fellowship at the Mayo Clinic in Rochester, MN.

Michael Brooks, PhD, MBA

President
Dr. Brooks has been with Edesa since 2015. He is responsible for day to day operations and for all corporate and business development activities. Prior to Edesa, he spent a number of years at Cipher Pharmaceuticals, (TSX:CPH), most recently as Director of Business Development. Michael holds an PhD from the University of Toronto and an MBA from the Rotman School of Management at U of T where he was a CIHR Science to Business Scholar.

Blair Gordon, PhD

Vice President, Research and Development
Dr. Gordon is responsible for the design, management, and execution of Edesa’s clinical programs. He completed his PhD studies at the University of Toronto in the Department of Molecular Genetics where he was an NSERC Alexander Graham Bell Fellow. His previous roles include Business Development at Cipher Pharmaceuticals (TSX:CPH) and Medical Affairs at ArcticDX. Dr. Gordon is excited to be commercializing scientific discoveries at Edesa.

Board of Directors

Par Nijhawan

Dr. Nijhawan is a board-certified Gastroenterologist and Hepatologist. Prior to founding Edesa, Dr. Nijhawan was the CEO of Medical Futures Inc. which he sold to Tribute Pharmaceuticals in 2015. Dr Nijhawan completed his medical school training at the University of Ottawa and did his residency in Internal Medicine Internship at Yale-Norwalk, CT; and Internal Medicine residency and Gastroenterology and Hepatology fellowship at the Mayo Clinic in Rochester, MN.

Peter van der Velden

Peter van der Velden is the Managing General Partner of Lumira Ventures. With 26 years of investment and operating experience, Peter has participated in building companies from start-up through to expansion in the life sciences, information technology and consumer sectors. Known as results-oriented entrepreneur with demonstrated success in venture and buyout investing, transaction structuring and completion, strategic planning, business development, and operational management and restructuring, Peter has established a strong reputation for leadership, consensus building, judgment, integrity and clarity of vision.

Paul Pay

Paul Pay is the Chief Business Development Officer at Norgine. Paul has over 35 years’ experience in the pharmaceutical industry in a range of commercial roles. These have covered sales, marketing, market research, licensing, business development and general management. Paul joined Norgine in November 2002. Prior to that he worked for a number of companies covering Big Pharma (Wellcome, Fisons), “biotechs” (Xenova, Andaris) and a university spin-out (Aegis). He has worked in the UK and the USA.

Michael Degasperis

Vice President, TACC Group of Companies. Recognized as one of the top 50 Entrepreneurs in Canada by the Richard Ivey School of Business and is a recipient of the Queen Elizabeth II Diamond Jubilee Medal. Member of BILD and TARION, DeGasperis has received several awards, including: Entrepreneur of the Year, Builder of the Year, Business of the Year, the Presidential Award of Merit, the coveted Award of Excellence and The Lifetime Achievement award from Vaughan Chamber of Commerce and the Natural Resources Canada recognized Arista Homes as the EnergyStar New Home Builder of the Year while The National Congress of Italian Canadians awarded him with the Ordine al Merito award.

Sean MacDonald

Mr. Sean A. MacDonald serves as Head of Business Development at Pharmascience Inc. Prior to this, Mr. MacDonald served as the Business Development Director at Ablynx NV. Mr. MacDonald also previously served as an Associate Director of Business Development and Licensing at Debiovision Inc. Mr. MacDonald has held business development positions at H3 Pharma Inc of Montreal and Canada. He has 15 yearsof experience in venture capital, commercial development, and deal-making.

Partners and Investors

Image
Image
Image
Image
Image
 

News & Articles